Zobrazeno 1 - 10 of 65 pro vyhledávání: '"B Kasimis"'
1
A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer
Autor: J. Shultz, Nancy E. Kemeny, R. Isaacs, Charles D. Blanke, Malcolm J. Moore, John Cox, Daniel G. Haller, B. Kasimis, M. Modiano, Richard L. Schilsky, D. Carlin, J. Fleagle, L. Hammershaimb
Publikováno v: Annals of Oncology. 13:87-91
Background Trimetrexate (TMTX) biochemically modulates 5-fluorouracil (5-FU) and leucovorin (LCV). Two phase II trials demonstrated promising activity for TMTX/5-FU/LCV in patients with untreated advanced colorectal cancer (ACC). This trial was desig
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::316fc4f9abfac3df262b6edd3724612a
https://doi.org/10.1093/annonc/mdf043
Zobrazit plný text záznamu
2
Age of first exposure to American football and long-term neuropsychiatric and cognitive outcomes
Autor: Robert S. Stern, Jesse Mez, Robert C. Cantu, Christopher J. Nowinski, Melissa Mariani, Yorghos Tripodis, Michael L. Alosco, Brett M. Martin, Clifford A. Robbins, J Hayden, Christine M. Baugh, Alicia S. Chua, Michael D. McClean, A B Kasimis, Shannon Conneely, Ann C. McKee, Alcy Torres, Rhoda Au, Julie Stamm, Daniel H. Daneshvar, Christine E. Chaisson
Publikováno v: Translational Psychiatry
Previous research suggests that age of first exposure (AFE) to football before age 12 may have long-term clinical implications; however, this relationship has only been examined in small samples of former professional football players. We examined th
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7647e2321cb9568198b63c3f60399a79
https://doi.org/10.1038/tp.2017.197
Zobrazit plný text záznamu
4
A retrospective analysis of cardiovascular morbidity in metastatic hormone-refractory prostate cancer patients on high doses of the selective COX-2 inhibitor celecoxib
Autor: Q Xia, R G Oriscello, Victor T. Chang, R A Madan, B Kasimis
Publikováno v: Expert opinion on pharmacotherapy. 8(10)
This data were previously presented in February 2007 at the American Society of Clinical Oncology's Prostate Cancer Symposium in Orlando, FL, USA. COX-2 inhibition has shown promise in treating prostate cancer, but concerns exist regarding the risk p
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1e45f79dbac4a95b569444b728ce55b
https://pubmed.ncbi.nlm.nih.gov/17661725
Zobrazit plný text záznamu
5
Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer
Autor: Charles D. Blanke, R Capizzi, M Kurman, B. Kasimis, P. Schein
Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 15(3)
PURPOSE A phase II study to evaluate the response rate and toxicities of a trimetrexate, fluorouracil (5FU), and leucovorin regimen in patients with advanced incurable colorectal cancer. PATIENTS AND METHODS Thirty-six patients with unresectable or m
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76228be99e7c5faef10a2b14d4716bff
https://pubmed.ncbi.nlm.nih.gov/9060528
Zobrazit plný text záznamu
6
Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group
Autor: B J, Roth, B Y, Yeap, G, Wilding, B, Kasimis, D, McLeod, P J, Loehrer
Publikováno v: Cancer. 72(8)
Recent clinical trials have documented activity for combinations of chemotherapeutic agents that target the microtubular apparatus in patients with hormone-refractory prostate cancer. Taxol has a novel antimicrotubular mechanism, acting by stabilizin
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::94f57a71a1c13ad5660d03a344a50936
https://pubmed.ncbi.nlm.nih.gov/8104680
Zobrazit plný text záznamu
8
A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy
Autor: W. H. Harvey, G. G. Monaghan, Paul J. Hesketh, D Gandara, Kelly Pendergrass, G Harker, D Oblon, B Kasimis, John D. Hainsworth, A Khojasteh
Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 9(5)
Ondansetron (GR 38032F), a selective antagonist of serotonin subtype 3 receptors, is effective in the prevention of emesis associated with cisplatin as well as other chemotherapeutic agents. In this randomized, single-blind, multicenter, parallel gro
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d3f8fb38bf624a4c016f21c041e04b9
https://pubmed.ncbi.nlm.nih.gov/1826738
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje